Companies
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The BioPharma Shares Rising On Omicron Hopes And Fears
Adagio Therapeutics and Gritstone bio are two companies who could add to the armamentarium against Omicron.
Vertex Secures Phase II Win In Rare Kidney Condition
The firm’s sole nephrological asset has demonstrated proof of concept, helping advance the novel gene-targeted therapy into pivotal development early next year.
Ex-Novartis Exec Unveils Neurodegeneration Gene Therapy Start-Up AviadoBio
AviadoBio believes it can overcome barriers to making gene therapy work in neurodegenerative diseases, and its new CEO knows what it takes to make a commercial success in the field.
GSK Poaches New Vaccines R&D Chief From Pfizer
Phil Dormitzer has been headhunted to help GSK get up to speed in RNA and other vaccine platforms.
Abogen and Neurophth Lead China mRNA, Gene And Cell Therapy Funding Rush
Total of $571m raised in China from 10 venture capital and private equity funding deals betting heavily on mRNA and targeted oncology, as well as gene and cell therapies.
SynAct Surveys Its Options As Rheumatoid Arthritis Asset Succeeds At Phase II
The company’s lead candidate, AP1189, has shown promise in a mid-stage rheumatoid arthritis study, sparking plans for an imminent strategic business collaboration.
The Biotech Rollercoaster Ride: From Lab To Buyout
After investing more than €23m in Sanifit, the Spanish firm being acquired by Vifor Pharma, Caixa Capital's director of life sciences investments spoke to Scrip about the venture capital firm's long-term approach.
China’s First Insulin Tender Hits Multinationals Hard
An average overall price reduction of 48% for insulin products in China is expected to generate annual savings of $1.4bn through 2023, but multinational pharma firms will be hit hard by the bidding process.
GSK Looks To Long-Acting Therapy To Restore Lead In HIV
GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.
Stock Watch: Drug Safety In The Spotlight
Are three FDA clinical holds in less than four days a symptom of lax safety programs at some biotech companies? And what does the latest publication on Aduhelm say about the relationship between safety and accelerated approval?
NRx’s COVID-19 Vaccine Candidate BriLife Impresses In Phase II
NRx’s BriLife has demonstrated strong potential in early data from a mid-stage COVID-19 trial, spurring the company on to begin a Phase IIb/III study as soon as possible.
COVID-19 Vaccine Makers Pledge Rapid Response To Omicron Threat
While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.